Search Results

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has disclosed certain historical and pro forma financial information with respect to its previously announced proposed acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5% and certain other ophthalmology assets (the “Acquisition”) on a Current Report on Form 8-K and on its SEDAR+ (www.sedarplus.ca) profile.

Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.

Initiates Development of Tailored Innovative Targeted Therapy for Refractory Cancer ReCerise Therapeutics Inc., has announced its selection for a grant from the Ministry of Trade, Industry and Energy of South Korea.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.

Forma Medical , an emerging innovator in medical device technologies, announces today the launch of OptimalHT, the world’s first instrumented Minimally Invasive Surgery (MIS) Hammertoe Arthrodesis procedure, that has treated more than 50 hammertoe deformities.